Deal Snapshot: The company told Scrip that part of why it licensed Arvinas’s ARV-766 and took over AR-V7 was to complement its radioligand therapy platform in prostate cancer.

New deal shows growing big pharma interest in protein degradation, with C4 expecting multiple in-house updates this year.

Several Chinese biotech developments during the Lunar New Year break have put investors on high alert, namely the continued share price slide of Chinese biotech bellwether WuXi Apptec, Lianbio ceasing operations and I-Mab divesting its China business to become a fully US-focused company.

The recent success of Vertex in acute pain merely highlights the agonizingly slow process elsewhere, particularly in chronic pain indications.